(PTCT) PTC Therapeutics - Ratings and Ratios
Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi
PTCT EPS (Earnings per Share)
PTCT Revenue
Description: PTCT PTC Therapeutics
PTC Therapeutics Inc (NASDAQ:PTCT) is a biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for rare disorders. The companys product portfolio includes Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi, targeting conditions such as Duchenne muscular dystrophy, aromatic l-amino acid decarboxylase deficiency, and spinal muscular atrophy.
From a business perspective, PTC Therapeutics has established collaborations with major pharmaceutical companies, including F. Hoffman-La Roche Ltd. and Novartis Pharmaceuticals Corporation, to advance its pipeline products. The companys development pipeline is robust, with Sepiapterin, PTC518, and vatiquinone being key candidates targeting phenylketonuria, Huntingtons disease, and Friedreichs ataxia, respectively.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, product adoption rates, and pipeline progress are crucial. Notably, the companys revenue has been driven by the sales of its marketed products, including Upstaza, which is sold under the brand name Kebilidi in the United States. Additionally, metrics such as research and development (R&D) expenses as a percentage of revenue, and the companys cash burn rate, will be essential in assessing its financial sustainability.
From a valuation perspective, PTCTs market capitalization stands at approximately $3.9 billion, with a forward price-to-earnings (P/E) ratio of 5.51, indicating a relatively low valuation compared to its peers. However, the companys return on equity (RoE) is negative, at -71.70%, suggesting that it is not generating profits. As a Trading Analyst, it is essential to closely monitor the companys progress in advancing its pipeline products, achieving regulatory approvals, and driving revenue growth to assess its potential for future profitability.
PTCT Stock Overview
| Market Cap in USD | 4,608m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-06-20 |
PTCT Stock Ratings
| Growth Rating | 33.8% |
| Fundamental | 84.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 45.9% |
| Analyst Rating | 4.0 of 5 |
PTCT Dividends
Currently no dividends paidPTCT Growth Ratios
| Growth Correlation 3m | 50.7% |
| Growth Correlation 12m | 63.1% |
| Growth Correlation 5y | -17.4% |
| CAGR 5y | 6.43% |
| CAGR/Max DD 3y | 0.09 |
| CAGR/Mean DD 3y | 0.22 |
| Sharpe Ratio 12m | 0.35 |
| Alpha | 0.03 |
| Beta | 0.701 |
| Volatility | 56.24% |
| Current Volume | 2263.1k |
| Average Volume 20d | 1264.4k |
| Stop Loss | 58.4 (-3.7%) |
| Signal | 0.81 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (629.2m TTM) > 0 and > 6% of Revenue (6% = 105.9m TTM) |
| FCFTA 0.28 (>2.0%) and ΔFCFTA 43.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 93.21% (prev 83.08%; Δ 10.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.27 (>3.0%) and CFO 704.8m > Net Income 629.2m (YES >=105%, WARN >=100%) |
| Net Debt (-629.2m) to EBITDA (838.5m) ratio: -0.75 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (78.2m) change vs 12m ago 1.86% (target <= -2.0% for YES) |
| Gross Margin 99.94% (prev 77.74%; Δ 22.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 77.57% (prev 46.99%; Δ 30.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.51 (EBITDA TTM 838.5m / Interest Expense TTM 147.1m) >= 6 (WARN >= 3) |
Altman Z'' 1.92
| (A) 0.62 = (Total Current Assets 2.27b - Total Current Liabilities 627.8m) / Total Assets 2.63b |
| (B) -1.08 = Retained Earnings (Balance) -2.85b / Total Assets 2.63b |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) 0.36 = EBIT TTM 810.4m / Avg Total Assets 2.28b |
| (D) -1.00 = Book Value of Equity -2.84b / Total Liabilities 2.84b |
| Total Rating: 1.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.75
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 25.65% = 5.0 |
| 3. FCF Margin 42.46% = 7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 0.36 = 2.40 |
| 6. ROIC - WACC (= 368.5)% = 12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 34.31% = 2.57 |
| 9. EPS Trend 55.46% = 2.77 |
What is the price of PTCT shares?
Over the past week, the price has changed by +3.98%, over one month by +21.79%, over three months by +19.27% and over the past year by +72.94%.
Is PTC Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PTCT is around 58.11 USD . This means that PTCT is currently overvalued and has a potential downside of -4.19%.
Is PTCT a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the PTCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 66.7 | 10% |
| Analysts Target Price | 66.7 | 10% |
| ValueRay Target Price | 64.8 | 6.9% |
Last update: 2025-09-05 04:56
PTCT Fundamental Data Overview
CCE Cash And Equivalents = 1.99b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 7.8818
P/E Forward = 6.006
P/S = 2.611
P/B = 1743.2734
P/EG = 0.81
Beta = 0.527
Revenue TTM = 1.76b USD
EBIT TTM = 810.4m USD
EBITDA TTM = 838.5m USD
Long Term Debt = 286.0m USD (from longTermDebt, last quarter)
Short Term Debt = 17.1m USD (from shortTermDebt, last quarter)
Debt = 303.1m USD (Calculated: Short Term 17.1m + Long Term 286.0m)
Net Debt = -629.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.92b USD (4.61b + Debt 303.1m - CCE 1.99b)
Interest Coverage Ratio = 5.51 (Ebit TTM 810.4m / Interest Expense TTM 147.1m)
FCF Yield = 25.65% (FCF TTM 749.5m / Enterprise Value 2.92b)
FCF Margin = 42.46% (FCF TTM 749.5m / Revenue TTM 1.76b)
Net Margin = 35.65% (Net Income TTM 629.2m / Revenue TTM 1.76b)
Gross Margin = 99.94% ((Revenue TTM 1.76b - Cost of Revenue TTM 1.08m) / Revenue TTM)
Tobins Q-Ratio = -1.03 (set to none) (Enterprise Value 2.92b / Book Value Of Equity -2.84b)
Interest Expense / Debt = 10.02% (Interest Expense 30.4m / Debt 303.1m)
Taxrate = 21.0% (US default)
NOPAT = 640.2m (EBIT 810.4m * (1 - 21.00%))
Current Ratio = 3.62 (Total Current Assets 2.27b / Total Current Liabilities 627.8m)
Debt / EBITDA = 0.36 (Net Debt -629.2m / EBITDA 838.5m)
Debt / FCF = 0.40 (Debt 303.1m / FCF TTM 749.5m)
Total Stockholder Equity = -636.2m (last 4 quarters mean)
RoA = 23.89% (Net Income 629.2m, Total Assets 2.63b )
RoE = unknown (Net Income TTM 629.2m / Total Stockholder Equity -636.2m)
RoCE = unknown (Ebit 810.4m / (Equity -636.2m + L.T.Debt 286.0m))
RoIC = 377.0% (NOPAT 640.2m / Invested Capital 169.8m)
WACC = 8.56% (E(4.61b)/V(4.91b) * Re(8.60%)) + (D(303.1m)/V(4.91b) * Rd(10.02%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.79%
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.67% ; FCFE base≈749.5m ; Y1≈506.5m ; Y5≈245.4m
Fair Price DCF = 54.78 (DCF Value 4.35b / Shares Outstanding 79.4m; 5y FCF grow -37.88% → 3.0% )
EPS Correlation: 55.46 | EPS CAGR: 17.24% | SUE: 0.06 | # QB: 0
Revenue Correlation: 34.31 | Revenue CAGR: -6.80% | SUE: N/A | # QB: None
Additional Sources for PTCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle